J Pharmacoepidemiol Risk Manage.  2022 Sep;14(2):101-108. 10.56142/jperm.22.0007.

Systematic Review for Remdesivir Use in Pediatric Patients under 3.5 kg with COVID-19

• Cho WB
• Lee NY
• Ah YM

• KMID: 2534680
• DOI: http://doi.org/10.56142/jperm.22.0007

Abstract

Objective
We aimed to identify the safety and efficacy of remdesivir in pediatric COVID-19 patients less than 3.5 kg by systematic review.
Methods
We conducted a literature search using MEDLINE, EMBASE, CENTRAL, and Google scholar based on keywords about remdesivir and neonates or infants. We also did a hand search using bibliography information of related literature. The literature reporting remdesivir use for COVID-19 treatment in pediatric patients under 3.5 kg were selected. Two researchers performed study selection and data extraction. The Joanna Briggs Institute (JBI) critical appraisal checklist was used to evaluate the quality of the included literature.
Results
Finally, 7 out of 8 patients were selected among 1,478 studies searched. Mechanical ventilation was applied to all cases, remdesivir were administered for 4 or 10 days using the normal dose or half of the normal dose. In 7 out of 8 cases, the condition of the child was reported to have improved after remdesivir use, and remdesivir associated adverse drug events were not identified.
Conclusion
Considering the clinical outcomes of case reports about remdesivir use in pediatric patients less than 3.5 kg in this study, remdesivir might be one of treatment strategies for pediatric patients less than 3.5 kg requiring mechanical ventilation. However, additional studies are needed to confirm the evidence of remdesivir for pediatric patients.

Keyword

Remdesivir; SARS-CoV2; COVID-19; Systematic review; Pediatric; Neonate